Skip to contents

Bradley Allen Maron, MD
Associate Physician, Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Cardiovascular
75 Francis Street
Boston, MA 02115


Edit Profile


Research Narrative:

Dr. Maron is a cardiologist and vascular biologist whose research emphasis involves understanding the contribution of protein cysteinly thiol oxidation to pulmonary vascular disease pathobiology. His recent work demonstrated that aldosterone, which is present at elevated concentrations in the pulmonary arterial circulation of patients with pulmonary arterial hypertension (PAH), increases pulmonary vascular oxidant stress to promote pulmonary vascular dysfunction that is due, in part, to decreased levels of bioavailable nitric oxide. Dr. Maron demonstrated in pulmonary endothelial cells that aldosterone-induced oxidant stress oxidatively modifies three functionally essential endothelin type-B (ETB) receptor cysteines to impair ETB-dependent nitric oxide synthesis in cells in vitro, which was associated with pathological pulmonary vascular remodeling and pulmonary hypertension in animals in vivo. The identification of an ETB redox “switch” is supported by preliminary clinical data suggesting that pharmacological inhibition of aldosterone may be an under recognized therapy for patients with PAH, and has stimulated several additional on-going avenues of scientific investigation that aim to leverage small molecule inhibitor technology to prevent the adverse of effects of aldosterone-(in)dependent oxidant stress on the redox status of key ETB cysteinyl thiols in order to prevent/attenuate pulmonary vascular dysfunction in PAH by maintaining normal ETB signal transduction.


Education:
Brown Medical School, 2003, MD

Publications (Pulled from Harvard Catalyst Profiles):

1. Gillmeyer KR, Lee KM, Shao Q, Miller DR, Maron BA, Klings ES, Rinne ST, Soylemez Wiener R. Multisystem Healthcare Use among U.S. Veterans with Pulmonary Hypertension. Ann Am Thorac Soc. 2019 Aug; 16(8):1072-1074.

2. Simon MA, Maron BA. Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction. Where to Draw the Line. Am J Respir Crit Care Med. 2019 Aug 01; 200(3):278-279.

3. Maron BA, Choudhary G, Tedford RJ, Brittain E. Correspondence on the debate regarding the haemodynamic definition of pulmonary hypertension. Eur Respir J. 2019 Jun; 53(6).

4. Maron BA, Wertheim BM. Toward Early Diagnosis of Pulmonary Hypertension: Lessons From Oz. J Am Coll Cardiol. 2019 Jun 04; 73(21):2673-2675.

5. Maron BA. Back to the Future: Building Up the Case for Exploring Red Blood Cell Morphology in Pulmonary Arterial Hypertension. Ann Am Thorac Soc. 2019 May; 16(5):548-550.

6. Maron BJ, Maron MS, Maron BA, Loscalzo J. Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week. J Am Coll Cardiol. 2019 Apr 23; 73(15):1978-1986.

7. Maron BA, Ryan JJ. A Concerning Trend for Patients With Pulmonary Hypertension in the Era of Evidence-Based Medicine. Circulation. 2019 Apr 16; 139(16):1861-1864.

8. Leopold JA, Maron BA. Precision Medicine in Pulmonary Arterial Hypertension. Circ Res. 2019 Mar 15; 124(6):832-833.

9. Wertheim BM, Lin YD, Zhang YY, Samokhin AO, Alba GA, Arons E, Yu PB, Maron BA. Isolating pulmonary microvascular endothelial cells ex vivo: Implications for pulmonary arterial hypertension, and a caution on the use of commercial biomaterials. PLoS One. 2019; 14(2):e0211909.

10. Maron BA, Wilkins MR. TORward a Molecular Convergence Point in Pulmonary Arterial Hypertension With mTOR. JACC Basic Transl Sci. 2018 Dec; 3(6):763-765.